Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
J Int Med Res ; 52(5): 3000605241253756, 2024 May.
Artículo en Inglés | MEDLINE | ID: mdl-38796313

RESUMEN

Prostatic stromal tumors, encompassing prostatic sarcoma and stromal tumors of uncertain malignant potential (STUMP), represent an exceedingly rare category of prostatic diseases, with a prevalence of less than 1%. We present a rare case involving a man in his early 40s diagnosed with STUMP. Despite presenting with normal prostate-specific antigen (PSA) concentrations, the patient experienced persistent dysuria and gross hematuria for >7 months, leading to an initial misdiagnosis of benign prostatic hyperplasia. Persistent symptoms prompted further investigation, with magnetic resonance imaging (MRI) revealing a suspicious lesion on the left side of the prostate, initially thought to be malignant. Transrectal prostatic biopsy subsequently confirmed the presence of mucinous liposarcoma, with no medical history of diabetes, coronary heart disease, or hypertension. The treatment approach comprised robot-assisted laparoscopic radical prostatectomy, culminating in a postoperative pathological definitive diagnosis of STUMP. This case underscores the indispensable role of early MRI in the diagnostic process, highlighting the necessity of detailed pathological examination for a conclusive diagnosis. Our report aims to illuminate the diagnostic challenges and potential treatment pathways for STUMP, emphasizing its consideration in the differential diagnosis of prostatic tumors to advance clinical outcomes in this rare but important condition.


Asunto(s)
Imagen por Resonancia Magnética , Neoplasias de la Próstata , Humanos , Masculino , Neoplasias de la Próstata/patología , Neoplasias de la Próstata/cirugía , Neoplasias de la Próstata/diagnóstico , Neoplasias de la Próstata/diagnóstico por imagen , Adulto , Diagnóstico Diferencial , Prostatectomía , Próstata/patología , Próstata/cirugía , Próstata/diagnóstico por imagen , Antígeno Prostático Específico/sangre , Hiperplasia Prostática/cirugía , Hiperplasia Prostática/patología , Hiperplasia Prostática/diagnóstico por imagen , Hiperplasia Prostática/diagnóstico , Sarcoma/patología , Sarcoma/cirugía , Sarcoma/diagnóstico , Sarcoma/diagnóstico por imagen
2.
Int J Nanomedicine ; 19: 3677-3695, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-38681092

RESUMEN

Bladder cancer, a prevalent malignant neoplasm of the urinary tract, exhibits escalating morbidity and mortality rates. Current diagnosis standards rely on invasive and costly cystoscopy and histopathology, underscoring the urgency for non-invasive, high-throughput, and cost-effective novel diagnostic techniques to ensure timely detection and standardized treatment. Recent years have witnessed the rise of exosome research in bladder cancer studies. Exosomes contain abundant bioactive molecules that can help elucidate the intricate mechanisms underlying bladder cancer pathogenesis and metastasis. Exosomes hold potential as biomarkers for early bladder cancer diagnosis while also serving as targeted drug delivery vehicles to enhance treatment efficacy and mitigate adverse effects. Furthermore, exosome analyses offer insights into the complex molecular signaling networks implicated in bladder cancer progression, revealing novel therapeutic targets. This review provides a comprehensive overview of prevalent exosome isolation techniques and highlights the promising clinical utility of exosomes in both diagnostic and therapeutic applications in bladder cancer management.


Asunto(s)
Biomarcadores de Tumor , Exosomas , Neoplasias de la Vejiga Urinaria , Exosomas/metabolismo , Humanos , Neoplasias de la Vejiga Urinaria/metabolismo , Biomarcadores de Tumor/metabolismo , Sistemas de Liberación de Medicamentos/métodos , Animales
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...